Cargando…

Asymptomatic Bacteriuria Escherichia coli Are Live Biotherapeutics for UTI

Urinary tract infections (UTI) account for approximately 8 million clinic visits annually with symptoms that include acute pelvic pain, dysuria, and irritative voiding. Empiric UTI management with antimicrobials is complicated by increasing antimicrobial resistance among uropathogens, but live bioth...

Descripción completa

Detalles Bibliográficos
Autores principales: Rudick, Charles N., Taylor, Aisha K., Yaggie, Ryan E., Schaeffer, Anthony J., Klumpp, David J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236008/
https://www.ncbi.nlm.nih.gov/pubmed/25405579
http://dx.doi.org/10.1371/journal.pone.0109321
_version_ 1782345089373175808
author Rudick, Charles N.
Taylor, Aisha K.
Yaggie, Ryan E.
Schaeffer, Anthony J.
Klumpp, David J.
author_facet Rudick, Charles N.
Taylor, Aisha K.
Yaggie, Ryan E.
Schaeffer, Anthony J.
Klumpp, David J.
author_sort Rudick, Charles N.
collection PubMed
description Urinary tract infections (UTI) account for approximately 8 million clinic visits annually with symptoms that include acute pelvic pain, dysuria, and irritative voiding. Empiric UTI management with antimicrobials is complicated by increasing antimicrobial resistance among uropathogens, but live biotherapeutics products (LBPs), such as asymptomatic bacteriuria (ASB) strains of E. coli, offer the potential to circumvent antimicrobial resistance. Here we evaluated ASB E. coli as LBPs, relative to ciprofloxacin, for efficacy against infection and visceral pain in a murine UTI model. Visceral pain was quantified as tactile allodynia of the pelvic region in response to mechanical stimulation with von Frey filaments. Whereas ciprofloxacin promoted clearance of uropathogenic E. coli (UPEC), it did not reduce pelvic tactile allodynia, a measure of visceral pain. In contrast, ASB E. coli administered intravesically or intravaginally provided comparable reduction of allodynia similar to intravesical lidocaine. Moreover, ASB E. coli were similarly effective against UTI allodynia induced by Proteus mirabilis, Enterococccus faecalis and Klebsiella pneumoniae. Therefore, ASB E. coli have anti-infective activity comparable to the current standard of care yet also provide superior analgesia. These studies suggest that ASB E. coli represent novel LBPs for UTI symptoms.
format Online
Article
Text
id pubmed-4236008
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-42360082014-11-21 Asymptomatic Bacteriuria Escherichia coli Are Live Biotherapeutics for UTI Rudick, Charles N. Taylor, Aisha K. Yaggie, Ryan E. Schaeffer, Anthony J. Klumpp, David J. PLoS One Research Article Urinary tract infections (UTI) account for approximately 8 million clinic visits annually with symptoms that include acute pelvic pain, dysuria, and irritative voiding. Empiric UTI management with antimicrobials is complicated by increasing antimicrobial resistance among uropathogens, but live biotherapeutics products (LBPs), such as asymptomatic bacteriuria (ASB) strains of E. coli, offer the potential to circumvent antimicrobial resistance. Here we evaluated ASB E. coli as LBPs, relative to ciprofloxacin, for efficacy against infection and visceral pain in a murine UTI model. Visceral pain was quantified as tactile allodynia of the pelvic region in response to mechanical stimulation with von Frey filaments. Whereas ciprofloxacin promoted clearance of uropathogenic E. coli (UPEC), it did not reduce pelvic tactile allodynia, a measure of visceral pain. In contrast, ASB E. coli administered intravesically or intravaginally provided comparable reduction of allodynia similar to intravesical lidocaine. Moreover, ASB E. coli were similarly effective against UTI allodynia induced by Proteus mirabilis, Enterococccus faecalis and Klebsiella pneumoniae. Therefore, ASB E. coli have anti-infective activity comparable to the current standard of care yet also provide superior analgesia. These studies suggest that ASB E. coli represent novel LBPs for UTI symptoms. Public Library of Science 2014-11-18 /pmc/articles/PMC4236008/ /pubmed/25405579 http://dx.doi.org/10.1371/journal.pone.0109321 Text en © 2014 Rudick et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Rudick, Charles N.
Taylor, Aisha K.
Yaggie, Ryan E.
Schaeffer, Anthony J.
Klumpp, David J.
Asymptomatic Bacteriuria Escherichia coli Are Live Biotherapeutics for UTI
title Asymptomatic Bacteriuria Escherichia coli Are Live Biotherapeutics for UTI
title_full Asymptomatic Bacteriuria Escherichia coli Are Live Biotherapeutics for UTI
title_fullStr Asymptomatic Bacteriuria Escherichia coli Are Live Biotherapeutics for UTI
title_full_unstemmed Asymptomatic Bacteriuria Escherichia coli Are Live Biotherapeutics for UTI
title_short Asymptomatic Bacteriuria Escherichia coli Are Live Biotherapeutics for UTI
title_sort asymptomatic bacteriuria escherichia coli are live biotherapeutics for uti
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236008/
https://www.ncbi.nlm.nih.gov/pubmed/25405579
http://dx.doi.org/10.1371/journal.pone.0109321
work_keys_str_mv AT rudickcharlesn asymptomaticbacteriuriaescherichiacoliarelivebiotherapeuticsforuti
AT tayloraishak asymptomaticbacteriuriaescherichiacoliarelivebiotherapeuticsforuti
AT yaggieryane asymptomaticbacteriuriaescherichiacoliarelivebiotherapeuticsforuti
AT schaefferanthonyj asymptomaticbacteriuriaescherichiacoliarelivebiotherapeuticsforuti
AT klumppdavidj asymptomaticbacteriuriaescherichiacoliarelivebiotherapeuticsforuti